Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-13

Clinical Trial Update: Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and efficacy of T89 for prevention and treatment of Acute Mountain Sickness has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • T89

Snippet

Sponsor: Tasly Pharmaceuticals, Inc. | Conditions: Acute Mountain Sickness (AMS) | Phase 2 | Status: COMPLETED